Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NetraMark Holdings ( (TSE:AIAI) ) has shared an update.
NetraMark Holdings Inc. has entered into an agreement with AlgoTherapeutix SAS to enhance clinical trial design for ATX01, a treatment for chemotherapy-induced peripheral neuropathy. Utilizing NetraMark’s NetraAI platform, the collaboration aims to optimize trial design by analyzing patient data to identify responder personas and improve trial success through enriched patient populations. This partnership highlights AlgoTx’s commitment to leveraging advanced AI technologies to accelerate the development of transformative therapies for patients.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in the development of Generative Artificial Intelligence and Machine Learning solutions aimed at the pharmaceutical industry. Their innovative technology utilizes a novel topology-based algorithm to analyze patient data, enabling precise disease segmentation and patient classification for drug sensitivity and treatment efficacy.
YTD Price Performance: 42.16%
Average Trading Volume: 56,635
Technical Sentiment Signal: Buy
Current Market Cap: C$109.5M
See more data about AIAI stock on TipRanks’ Stock Analysis page.